Key Highlights
- Shares of CRSP plummeted by as much as 11.59% during Friday’s session, reaching an intraday low of $51.21
- First-quarter results disappointed significantly: loss per share of -$1.37 versus the anticipated -$1.15; sales totaled $0.86M compared to forecasts of $4.72M — representing a 97.8% year-over-year decline
- Competitive landscape shifted as Regeneron announced its gene therapy Otarmeni would be provided at no cost to qualifying U.S. patients, potentially impacting Casgevy’s premium pricing strategy
- Chief Executive Samarth Kulkarni divested 10,349 shares mid-March; company insiders collectively sold 51,828 shares in the preceding three-month period
- Wall Street analysts continue to rate the stock as a consensus “Moderate Buy” with a mean price objective of $64.53
Shares of CRISPR Therapeutics ($CRSP) experienced a challenging trading day on Friday. The biotechnology company’s stock declined as much as 11.59%, bottoming out at $51.21 during the session, ultimately closing near $51.04 — a significant retreat from the previous day’s close of $55.18. Trading volume registered approximately 1.36 million shares, running about 27% lighter than typical activity.
The sharp decline stemmed from a confluence of negative developments: disappointing quarterly financial results paired with emerging competitive challenges from Regeneron.
Regarding the financial performance, CRISPR disclosed a quarterly loss per share of -$1.37, falling short of Wall Street’s consensus projection of -$1.15. More troubling was the revenue figure of merely $0.86 million — dramatically below the anticipated $4.72 million. This represented a staggering 97.8% contraction compared to the same period in the prior year, blindsiding market participants.
The biotechnology firm’s return on equity remains deeply negative at -26.31%, while its net profit margin shows substantial losses. Wall Street projections currently anticipate a full-year loss per share of -$4.93.
Competitive Threat from Regeneron’s No-Cost Gene Therapy
Complicating matters further is Regeneron’s recent development. The pharmaceutical giant secured regulatory clearance for Otarmeni, a gene-based treatment that will be distributed without charge to qualifying U.S. patients. This represents a formidable challenge to the gene-editing industry’s traditional pricing framework.
CRISPR’s primary commercial product, Casgevy — created in partnership with Vertex Pharmaceuticals — commands a sticker price of $2.2 million. Investor concerns center on whether Regeneron’s zero-cost approach might trigger broader pricing discussions throughout the sector, potentially undermining the value proposition of high-priced single-administration treatments.
Casgevy achieved a historic regulatory milestone as the first CRISPR-based treatment to receive FDA authorization. However, commercial adoption has progressed more slowly than anticipated, and Regeneron’s strategic pricing decision introduces additional questions regarding future revenue generation.
Executive Stock Sales Contribute to Negative Sentiment
Internal trading patterns have further dampened investor confidence. Chief Executive Officer Samarth Kulkarni disposed of 10,349 shares on March 16 at a mean transaction price of $48.26, trimming his holdings by roughly 4%. On the identical date, General Counsel James Kasinger offloaded 3,450 shares.
Throughout the most recent three-month window, company insiders collectively divested 51,828 shares valued at approximately $2.58 million. Corporate insiders maintain ownership of 4.30% of outstanding shares.
While such divestiture activity isn’t uncommon among biotechnology executives managing equity-based compensation packages, it nonetheless contributes to the prevailing cautious atmosphere surrounding the security.
Analyst perspectives remain varied yet generally favorable. Bank of America maintains a Buy recommendation with an $89 price objective. Needham assigns a Buy rating with an $82 target. TD Cowen holds a Hold stance with a $45 projection. Citizens JMP rates the stock Market Outperform with an $80 target. The aggregate consensus stands at Moderate Buy, featuring an average price target of $64.53 — representing substantial upside from current trading levels.
Technical indicators show the stock’s 50-day moving average at $52.68 while the 200-day stands at $55.70. The company’s market capitalization hovers around $4.90 billion with a beta coefficient of 1.80.
Current trading activity positions CRSP near $51, continuing to trade beneath both significant moving average benchmarks.
